Second Sight’s second product might lead the company to second place in the market.
Pivotal data validate Aldeyra’s lead project, reproxalap, but there are questions about a lack of dose response.
Roche awaits a high-risk, high-reward readout in autism, while for Ocular Therapeutix placebo ought to be easier to beat than active control.
Biogen’s $877m buyout of Nightstar Therapeutics provides yet more evidence that gene therapy is reaching critical mass.
Promising retinitis pigmentosa results have given Reneuron a boost, but the company still faces a pivotal trial.
A deal between J&J and Meiragtx in eye disease shows growing interest from big pharma as gene therapy's commercial issues come into focus.
Aurinia's lead project shows promise in its back-up use of dry eye, but risks distracting the company from a late-stage lupus trial.
Two readouts are approaching for Axsome's AXS-05, and Aldeyra is facing a data-heavy 2019.
After failing in retinal vein occlusion, the prospects for the eye project Xipere – and Clearside Biomedical itself – hinge on the smaller uveitis indication.